Harren Jhoti is President and CEO of Astex Therapeutics, a small biotech he co-founded and where he has been a pioneer of new approaches to structure-guided drug discovery. Here he first demonstrated the power of fragment-based approaches using X-ray crystallography to make new medicines. Dr Jhoti designed and developed a vibrant fragment discovery platform from which multiple small molecule drug candidates were generated, validating this new approach and helping it gain acceptance within industry and academia, including seminal research publications. Several of these drug candidates in development continue to be progressed by pharmaceutical partners, such as Novartis and AstraZeneca, and have shown clinical benefit in cancer patients.
Fellow
Back to directory listingDr Harren Jhoti OBE FRS FMedSci
Job Title
Retired
Year elected
2015
Interests
SpecialitiesDrug discovery, structural biology, oncology, fragment-based drug discovery.
Section committee elected byPhysics, chemistry, biochemistry, structural biology, mathematical sciences including statistics, informatics, imaging and engineering applied to biomedicine